Denali Therapeutics Inc. — Director's Dealing 2021

Apr 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-03-31

Reporting Person: SATO VICKI L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-31	Common Stock	S	18	$54.38	Disposed	139069	Direct
2021-03-31	Common Stock	S	877	$55.911	Disposed	138192	Direct
2021-03-31	Common Stock	S	635	$56.921	Disposed	137557	Direct
2021-03-31	Common Stock	S	136	$57.606	Disposed	137421	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: Includes 3,253 restricted stock units.

F3: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.485 to $56.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.52 to $57.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.525 to $57.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.